학술논문
Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade
Document Type
article
Author
Crismita Dmello; Junfei Zhao; Li Chen; Andrew Gould; Brandyn Castro; Victor A. Arrieta; Daniel Y. Zhang; Kwang-Soo Kim; Deepak Kanojia; Peng Zhang; Jason Miska; Ragini Yeeravalli; Karl Habashy; Ruth Saganty; Seong Jae Kang; Jawad Fares; Connor Liu; Gavin Dunn; Elizabeth Bartom; Matthew J. Schipma; Patrick D. Hsu; Mahmoud S. Alghamri; Maciej S. Lesniak; Amy B. Heimberger; Raul Rabadan; Catalina Lee-Chang; Adam M. Sonabend
Source
Nature Communications, Vol 14, Iss 1, Pp 1-18 (2023)
Subject
Language
English
ISSN
2041-1723
Abstract
Immunotherapies have shown limited efficacy in patients with glioma. Here, based on an in vivo kinome knockout CRISPR screen, the authors show that checkpoint kinase 2 promotes CD8 T cell immune evasion and that its depletion or inhibition improve survival and response to PD1/PDL1 blockade in preclinical glioma models.